Share This Page
Drugs in ATC Class A07A
✉ Email this page to a colleague
Subclasses in ATC: A07A - INTESTINAL ANTIINFECTIVES
A07A Market Analysis and Financial Projection
The intestinal anti-infectives market (ATC Class A07A) is shaped by rising infectious diseases, antibiotic resistance challenges, and innovations targeting microbiome health. This analysis explores market dynamics, key players, patent trends, and growth opportunities.
Market Overview
The global intestinal anti-infectives market operates within the broader anti-infective agents sector, valued at USD 135.43 billion in 2024, growing at a CAGR of 1.61% through 2030[1]. Key drivers include:
- Rising infections: Increasing bacterial/fungal intestinal diseases due to poor hygiene and contaminated food/water[3].
- Antimicrobial resistance: Drug-resistant pathogens spur demand for novel therapies, including microbiome-protective agents[3][4].
- Innovative treatments: Recent approvals like EMBLAVEO (Pfizer) in Europe[1] and pipeline drugs like ibezapolstat (Acurx Pharmaceuticals)[4] highlight advancements.
Key Drug Segments
Antibiotics (A07AA)
Dominant subcategory including neomycin, streptomycin, and rifaximin. Nystatin, used for fungal infections, saw a U.S. market revenue surge from \$338,443 (2011) to \$730,397 (2017), supplied by Heritage, Sun, and Teva[6].
Emerging Therapies
- Ibezapolstat: Acurx Pharmaceuticals’ Phase 3 candidate targets C. difficile while preserving gut flora, supported by recent USPTO patents[4].
- SYN-004: Synthetic Biologics’ enzyme-based therapy neutralizes IV antibiotics in the gut to prevent C. difficile infections[11].
Patent Landscape
| Recent patents emphasize microbiome preservation and reduced recurrence: | Company | Drug/Technology | Key Features | Patent Highlights |
|---|---|---|---|---|
| Acurx | Ibezapolstat | Targets C. difficile recurrence | USPTO-granted patents for microbiome restoration[4] | |
| Synthetic Biologics | SYN-004 | Protects gut flora during IV antibiotic use | 25+ U.S./international patents covering composition and methods[11] | |
| Pfizer | EMBLAVEO | Broad-spectrum antibiotic for intra-abdominal infections | EC approval with streamlined regulatory pathways[1] |
Competitive IP strategies focus on antibiotic adjuvants, enzyme inhibitors, and combination therapies to overcome resistance[3][4].
Regional Insights
- North America: Holds 38.1% revenue share (2024) due to advanced healthcare infrastructure and initiatives like Cleveland Clinic’s women’s health center[1].
- Europe: Growth driven by regulatory support, e.g., EMBLAVEO’s approval[1].
- Asia-Pacific: Emerging opportunities due to rising awareness and government health programs[3].
Challenges and Opportunities
Challenges
- Antibiotic resistance: 60% of E. coli strains show resistance to first-line therapies[3].
- R&D costs: High expenditure for novel drug development[7].
Opportunities
- Microbiome-friendly therapies: Drugs like ibezapolstat offer reduced recurrence rates[4].
- Expanding markets: Partnerships in Asia-Pacific and Latin America to address unmet needs[3].
Competitive Landscape
Major players include Pfizer, Merck, Teva, and AstraZeneca, alongside biotech innovators like Acurx and Synthetic Biologics. Strategies emphasize:
- Portfolio diversification: Combining traditional antibiotics with adjuvants[7].
- Strategic patents: Securing IP for novel mechanisms and formulations[4][11].
Future Outlook
The market will hinge on precision therapies and regulatory agility, with a projected 6.6% CAGR for related intra-abdominal infection treatments through 2033[7]. Innovations in microbiome science and AI-driven drug discovery are poised to redefine treatment paradigms.
Key Insight: “Protecting the gut microbiome while treating infections is no longer optional—it’s a clinical imperative.” – Acurx Pharmaceuticals[4].
Key Takeaways
- Intestinal anti-infectives are critical in managing resistant infections.
- Patent filings prioritize microbiome protection and recurrence prevention.
- North America and Europe lead, but Asia-Pacific offers untapped potential.
- Collaborations between biotech and pharma giants will drive next-gen therapies.
FAQs
-
What distinguishes A07A-class drugs?
They specifically target intestinal pathogens while minimizing systemic effects. -
Why are microbiome-friendly drugs gaining traction?
They reduce recurrence by preserving beneficial gut bacteria[4][11]. -
How does antibiotic resistance impact this market?
It necessitates costly R&D for novel mechanisms[3]. -
Which regions offer growth opportunities?
Asia-Pacific due to rising healthcare investment[3]. -
What role do patents play in market competition?
They secure exclusivity for innovative formulations and methods[4][11].
References
- https://www.grandviewresearch.com/industry-analysis/anti-infective-agents-market
- https://en.wikipedia.org/wiki/ATC_code_A07
- https://www.biospace.com/intestinal-anti-infective-market-rising-predominance-of-intestinal-infections-is-the-key-factors-driving-the-market
- https://www.acurxpharma.com/news-media/press-releases/detail/83/uspto-grants-acurx-pharmaceuticals-new-patent-for
- https://www.frontiersin.org/journals/research-metrics-and-analytics/articles/10.3389/frma.2023.978249/full
- https://www.econ.queensu.ca/sites/econ.queensu.ca/files/wpaper/qed_wp_1474.pdf
- https://www.verifiedmarketreports.com/product/intra-abdominal-infection-treatment-drugs-market/
- https://www.atccode.com/A07
- https://patentbusinesslawyer.com/blockchain-patent-landscape-comprehensive-guide-for-2024-and-2025/
- https://ip.com/blog/2025-patent-trends-challenges-and-innovations-shaping-the-future-of-technology/
- https://www.biospace.com/synthetic-biologics-inc-announces-recent-international-patents-that-bolster-its-c-difficile-program
- https://www.knowmade.com/patent-analytics-services/patent-report/semiconductor-patent-landscape/semiconductor-advanced-packaging-patent-landscape/antenna-in-package-patent-landscape-2021/
More… ↓
